PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
Eligible age
65+ yrs
Accepts
All genders
Locations
27 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Sponsor: Edwards Lifesciences
Where it's recruiting
Huntsville
Tucson
Los Angeles · Pasadena · Rancho Mirage · San Francisco …
Loveland
New Haven
Gainesville · Jacksonville · Sarasota
Atlanta
Boise
Chicago · Lisle
Wichita
New Orleans
Boston
Source: ClinicalTrials.gov · NCT04889872 · last updated 2025-12-17